trial

Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia

NCTId NCT00361543
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 54 (actual)
Sponsored by The Alfred
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
54 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2006-08
Primary completion
2014-12
Eligibility
FEMALE · 45 Years · 70 Years

Interventions & indications

Drugs
Raloxifene HydrochlorideLactose Capsules

Sponsors

The AlfredLead Sponsor
Stanley Medical Research InstituteCollaborator
National Health and Medical Research Council, AustraliaCollaborator

Investigators

1
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHDPrincipal Investigator

Sites

1 total
Melbourne, Australia

Facts & assertions

4 sourced
Enrollment
54
Phase
PHASE4
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Raloxifene Hydrochloride
drug
Lactose Capsules
drug
lead_sponsor
The Alfred
company
collaborator
Stanley Medical Research Institute
company
National Health and Medical Research Council, Australia
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHD
person